Biomarin Pharmaceutical

Yahoo Finance • 10 days ago

What Makes BioMarin (BMRN) so Attractive

BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the 17 biotechnology stocks with more than 50% upside. As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment. Of the 15 analysts cov... Full story

Yahoo Finance • 10 days ago

BioMarin Debt Deal And VOXZOGO Approval Recast Rare Disease Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BioMarin Pharmaceutical (NasdaqGS:BMRN) has closed a large debt offering to help fund its pending acquisition of Amicus The... Full story

Yahoo Finance • 15 days ago

Pharma companies left out of Trump's drug-pricing deals look for way in

By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U.S. drug pricing are looking to craft their own deals in an attempt to avoid potentiall... Full story

Yahoo Finance • 17 days ago

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and gover... Full story

Yahoo Finance • 18 days ago

Veeva Systems Inc. (VEEV): Balancing Analyst Skepticism with Innovation and Strategic Partnerships

Veeva Systems (NYSE:VEEV) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Veeva Systems (NYSE:VEEV) unveiled Veeva eSource, a new Veeva SiteVault tailored to eliminate manual clinical trial processes and in... Full story

Yahoo Finance • 2 months ago

BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push

BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies to its portfolio. Under the terms of the agreement, BioMarin will pay cash for al... Full story

Yahoo Finance • 2 months ago

Key deals this week: Trump Media & Technology, Howard Hughes, BioMarin Pharmaceutical and more

[Documents about mergers and acquisitions m&a with a pen.] designer491 Here's a list of key deals reported across sectors this week: * BioMarin Pharmaceutical (BMRN [https://seekingalpha.com/symbol/BMRN]) has agreed to acquire [https:/... Full story

Yahoo Finance • 2 months ago

BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus

We recently published 10 Firms in the Limelight. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best performers on Friday. BioMarin Pharmaceutical extended its winning streak to a third straight day on Friday, surging 17.71 perc... Full story

Yahoo Finance • 2 months ago

Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger

We recently published 10 Firms in the Limelight. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus Therapeutics soared to a new 52-week high on Friday, jumping 30.21 percent to close at $14.18 apiece... Full story

Yahoo Finance • 3 months ago

BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the cheap healthcare stocks to buy heading into 2026. As reported by TheFly, Leerink reduced the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $60 from $82 and downgraded... Full story

Yahoo Finance • 3 months ago

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a fur... Full story

Yahoo Finance • 4 months ago

Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More

mezzotint / Shutterstock.com Pre-Market Futures: The futures are trading modestly higher on Thursday after a big snap-back rally on Wednesday, as all the major indices staged a solid rebound following the Tuesday sell-off. While some of... Full story

Yahoo Finance • 4 months ago

Why is BioMarin Pharmaceutical (BMRN) One of the Most Profitable Biotech Stocks to Buy?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on October 21 and set a price target of $90.BioMarin Pharmace... Full story

Yahoo Finance • 4 months ago

BioMarin outlines $900M–$935M VOXZOGO 2025 revenue target and plans ROCTAVIAN divestiture amid evolving competitive landscape

Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 MANAGEMENT VIEW * Alexander Hardy, President and CEO, reported "strong results across the business, leading us to raise full year total revenues guidance at the midpoi... Full story

Yahoo Finance • 4 months ago

BioMarin seeks to divest hemophilia A gene therapy Roctavian

[BioMarin] hapabapa * BioMarin Pharmaceutical (NASDAQ:BMRN [https://seekingalpha.com/symbol/BMRN]) said it will look to divest Roctavian (valoctocogene roxaparvovec), a one-time gene therapy for hemophilia A to focus more on its core tr... Full story

Yahoo Finance • 4 months ago

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook 2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than 20% Revenue Growth for PALYNZIQ and VOXZOGO BioMarin Focuses Commercia... Full story

Yahoo Finance • 4 months ago

Biomarin Pharmaceutical Q3 25 Earnings Conference Call At 4:30 PM ET

(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will host a conference call at 4:30 PM ET on October 27, 2025, to discuss Q3 25 earnings results. To access the live webcast, log on to https://investors.biomarin.com/events-and-presentation... Full story

Yahoo Finance • 5 months ago

Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the most promising biotech stocks to buy according to hedge funds. In the second quarter, Tealwood Asset Management Inc. expanded its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN... Full story

Yahoo Finance • 5 months ago

Sum Up The Pieces: MDYV Could Be Worth $94

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 6 months ago

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Investing Case Study in Undervaluation

Value investing remains one of the most enduring investment strategies, focusing on identifying stocks trading below their intrinsic worth. The approach, pioneered by Benjamin Graham and later refined by investors like Warren Buffett, emph... Full story